Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 1; p. 9
• Main Authors: Sukhanov, Ilya, Dorotenko, Artem, Fesenko, Zoia, Savchenko, Artem, Efimova, Evgeniya V, Mor, Mikael S, Belozertseva, Irina V, Sotnikova, Tatyana D, Gainetdinov, Raul R
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21-12-2022; MDPI
• Subjects: Alzheimer's disease; Animals; Basal ganglia; Boxes; Carbidopa; Catalepsy; Catalepsy - complications; Catalepsy - drug therapy; Central nervous system diseases; Design of experiments; Dopamine; Dopamine transporter; dopamine transporter knockout rat; Drug development; Drug dosages; hypodopaminergia; Levodopa; Levodopa - pharmacology; Levodopa - therapeutic use; Locomotor activity; Movement disorders; Neurodegenerative diseases; Parkinson Disease - drug therapy; Parkinson Disease - etiology; Parkinson's disease; PDE10A inhibitors; Rats; Tyrosine 3-monooxygenase; St Petersburg Russia; Russia; hypodopaminergia; locomotor activity; PDE10A inhibitors; Parkinson’s disease; dopamine transporter knockout rat
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom13010009

Parkinson's disease is the second most common neurodegenerative pathology. Due to the limitations of existing therapeutic approaches, novel anti-parkinsonian medicines with non-dopamine mechanisms of action are clearly needed. One of the promising pharmacological targets for anti-Parkinson drug development is phosphodiesterase (PDE) 10A. The stimulating motor effects of PDE10A inhibition were detected only under the conditions of partial dopamine depletion. The results raise the question of whether PDE10A inhibitors are able to restore locomotor activity when dopamine levels are very low. To address this issue, we (1) developed and validated the rat model of acute severe dopamine deficiency and (2) tested the action of PDE10A inhibitor MP-10 in this model. All experiments were performed in dopamine transporter knockout (DAT-KO) rats. A tyrosine hydroxylase inhibitor, α-Methyl-DL-tyrosine (αMPT), was used as an agent to cause extreme dopamine deficiency. In vivo tests included estimation of locomotor activity and catalepsy levels in the bar test. Additionally, we evaluated the tissue content of dopamine in brain samples by HPLC analysis. The acute administration of αMPT to DAT-KO rats caused severe depletion of dopamine, immobility, and catalepsy (Dopamine-Deficient DAT-KO (DDD) rats). As expected, treatment with the L-DOPA and carbidopa combination restored the motor functions of DDD rats. Strikingly, administration of MP-10 also fully reversed immobility and catalepsy in DDD rats. According to neurochemical studies, the action of MP-10, in contrast to L-DOPA + carbidopa, seems to be dopamine-independent. These observations indicate that targeting PDE10A may represent a new promising approach in the development of non-dopamine therapies for Parkinson's disease.